A few hours after the closing bell of another relatively flat trading session, Pristine Solutions (OTC:PRTN) played their first joker: FDA approval. According to their release, Eaton Scientific Systems, Ltd., a wholly owned subsidiary of PRTN, commented on select details of its planned, multi-phase, multi-location clinic trials for FDA approval of its novel drug indication Tropine 3. The only FDA approval forthcoming would be from Falsely Documented Advertisements.
Looking for Hot Penny Stocks? Click here and get Alerts on the Best Penny Stocks FREE.
PRTN Stock Chart
Close: 0.385, up 0.019 (5.19%)
Dollar Volume: $7,067,317
Average Trade Size: 7,510
Gains since AimHigh Coverage: 71.11%
Dollar Volume Since 8/22: $50,968,555
Our New Alert Is Set For Mid-September! Click HERE To Make Sure You Don’t Miss It!
The late evening update goes on to state how the Company is presently finalizing preparations for what they believe, according to CEO Michael Borkowski, to be the landmark clinical studies of their drug Tropine 3. Get this guy a ticket to “The View” and let those women have a go at it. I guarantee there won’t be any kool aid served at that episode.
According to their statement to the public, Eaton intends to conduct multiple clinical trials in Phase 1-2 & Phase 3 of Tropine 3. The first trial is planned to be an FDA protocol approved “Phase 1-2, Prospective, Randomized, Double Blind, Placebo-Controlled, Dose Escalation, Parallel-Group Study to Test the Efficacy and Safety of Homatropine Methylbromide Oral Suspension on Selected Climacteric Symptoms and Quality of Life in Menopausal Women Not Receiving Hormonal Replacement Therapy (“HRT”)”.
The rumors have already begun to flow, as we vehemently warned about, that a DTC Chill may have been issued on PRTN. If such was the case, many online trading platforms will have issues executing trades on the pump and dump. We mentioned how Awesome Penny Stocks was on the FINRA watch list and how trading could easily come to an abrupt halt if they were to take action on their current promotion.
About PRTN Stock
Pristine Solutions, Inc., through its wholly-owned subsidiary company, Eaton Scientific Systems, Ltd., anticipates conducting the clinic trials at multiple sites across the United States and plans to publish the results in medical journals and women’s health publications. The Company intends to begin marketing Tropine 3 to pharmaceutical companies for potential acquisition following completion of the first Phase 1-2 clinic trial.
Bottom Line: PRTN is the top penny stock and leads all of the penny shares to watch for the remainder of the week. Other than the 71% gains for anyone who jumped on PRTN Friday, long traders are holding single digit gains for the most part. Assuming no DTC chill or FINRA action is taken, PRTN should top $3 by late September and the Red Sox will be winning the AL East as well.
Here is your opportunity to subscribe to the Most Read Penny Stock Newsletter
If You Can’t Make Money With Us, You Shouldn’t Be Trading Penny Stocks
(We are 100% Anti-Spam and will never rent or sell your information)Share